Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study
Breast conserving surgery followed by radiotherapy is the gold standard treatment for early breast cancer. Cases with unfavorable tumor volume to breast volume ratio or challenging localizations are at higher risk of margin infiltration or poor aesthetic outcomes. While margin infiltration represents one of the stronge
| Condition(s) | Breast Cancer, Oncoplastic Breast Surgery, Oncoplastic Breast-conserving Surgery, Chest Wall Perforator Flap |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Breast conserving surgery followed by radiotherapy is the gold standard treatment for early breast cancer. Cases with unfavorable tumor volume to breast volume ratio or challenging localizations are at higher risk of margin infiltration or poor aesthetic outcomes. While margin infiltration represents one of the strongest predictors of local recurrence, unappealing cosmetic results may significantly impair survivors' quality of life. Over the past two decades, the adoption of oncoplastic breast conserving surgery (OBCS) techniques has shown promise in improving both oncological and aesthetic outcomes after breast cancer surgery. Partial breast volume reconstruction (PBR) after OBCS is obtained through volume displacement (which involves remodelling and redistributing glandular tissue) and v |
| Who can participate | Inclusion Criteria: * Patients treated with BCS combined with CWPFs for primary stage I-III invasive cancer (IC) or ductal carcinoma in situ (DCIS); * Patients treated during the last 10 years (2015-2025); * Patients aged 18 years or more; * Cases with at least one-year follow-up. Exclusion Criteria: * Male Patients; * Patients aged less than 18 years; * Patients who underwent traditional breast conserving surgery or OBCS with displacement techniques; * Patients who underwent mastectomy; * Patients who underwent implant-based reconstruction; * Patients with unresectable breast cancer or metastatic disease; * Patients who were lost during follow-up. |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | Istituto Oncologico Veneto IRCCS |
| Locations | Padova, Italy |
| Start date | 2024-04-18 |
| NCT ID | NCT06906237 |
| Official listing | https://clinicaltrials.gov/study/NCT06906237 |